NEWS & INSIGHTS

Shortlisted for the Life Sciences Law Firm of 2020 – LMG Life Sciences

Our law firm has been shortlisted for the title of Life Sciences Law Firm of the Year in Poland, according to the international LMG Life Sciences legal ranking. We are very grateful for the received recognition and such a good feedback on the legal services provided by us.

Third place in Legal 500 EMEA 2020

  I am proud and happy to share the news that our law firm Monika Duszyńska Law for Lifesciences has been ranked in Tier 3 of this year edition of Legal 500, EMEA 2020, in Healthcare and Life Sciences. I am particularly honoured by the testimonials that were given on our work and commitment.

Conference Biological Medicines – legal aspects at UKSW

In December 2019 took place an annual nationwide scientific conference, organized by UKSW University in Warsaw, faculty of Law and Administration. Monika Duszyńska led the first panel, entitled „Patient under a biological treatment’’. The panel was attended, among others, by Prof. Marcin Czech and Paweł Grzesiewski, Director of Legal Affairs at the office of the Commissioner for Patients’ Rights, as well as representatives of patients' organizations.

Monika advises on the reimbursement of the costs of treatment obtained outside Poland

Monika advised the parents of a newborn with rare heart disorders in proceedings concerning reimbursement from the National Health Fund of the costs of very complicated surgery treatment obtained abroad (several hundred thousand zlotys). The President of the NFZ (National Health Fund) approved the reimbursement of these costs in full.

Monika as one of the authors of IZWOZ reports

Monika Duszyńska is one of the authors of the extensive report published by the Institute of Health Management at Lazarski University. "Reasons of a limited availability of medicines in Poland. Diagnosis and proposed solutions” is a detailed analysis of restricted market availability of certain medicines and suggests a number of potential solutions, in particular in the area of reimbursement and pharmaceutical regulations.  

The report “Costs of new drug technologies in the treatment of the most commonly diagnosed cancers. Forecast 2019-2021”

Monika Duszyńska is one of the authors of the report ‘Costs of new drug technologies in the treatment of the most commonly diagnosed cancers. Forecast 2019-2021’ prepared by the Institute of Health Management at Lazarski University. The report defines goals and tools required for an effective implementation of the health policy in the area of oncology.

Patients’ rights at Lazarski University

In April 2019 Monika Duszyńska conducted classes „Patients’ rights in connection with availability of healthcare services” at Lazarski University.

Debate „Biologicals and biosimilars – to make savings in order to be able to spend more”

On 30 July 2019 Monika Duszyńska took part in a panel in a debate „Biologicals and biosimilars – to make savings in order to be able to spend more”, organized by the Polish pharmaceutical industry chamber Izba Gospodarcza “Farmacja Polska”

Monika Duszyńska as an expert in the Polish Radio Channel 1

On 22 August Monika spoke, as an expert, in the Polish Radio, Channel 1, on biological medicines. We warmly invite you to listen to it (in Polish) at: https://www.polskieradio.pl/7/5098/Artykul/2357803,Sukces-inzynierii-genetycznej-lek-biologiczny  

Chambers Europe 2019

Interview for Rzeczpospolita

On 16 August 2018, Monika Duszyńska was interviewed by Paweł Rochowicz from Rzeczpospolita daily newspaper, where Monika spoke about biological and biosimilar medicines. We invite you to review the interview on-line at: https://www.rp.pl/RZECZoPRAWIE/180829956-Monika-Duszynska---Biorownowazny-nie-jest-wlasciwa-definicja-dla-lekow-biopodobnych.html

Public debate: “The medical reason of state – the theses for health”

On 29 June 2018, Monika Duszyńska attended a debate "Medical reason of state - the theses for health", under the Honorary Patronage of Fr. Cardinal Kazimierz Nycz. Her speech focused primarily on legislative challenges in healthcare.